RT Rapport Therapeutics, Inc. Stock: price and insider trades · United States · SEC (Form 4) Track the Rapport Therapeutics, Inc. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares trade on US US, under the oversight of SEC (Form 4). Market capitalisation: €2bn. The latest transaction was disclosed on 29 July 2026 (Cession). Among the most active insiders: Bredt David. The full history is openly available.
Analyst consensus: bullish or bearish? Analysts rate Rapport Therapeutics, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$58.59.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
Generate AI analysis AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 29 July 2026
All Executives50 Thresholds0 Prospectus0 Other0
Declarations 50 total
▼ Chief Executive Officer · Executives · 27 Jul 2026
2,203 shares @ US$42.107 Common Stock SEC:0001193125-26-323637:0
▼ Chief Executive Officer · Executives · 27 Jul 2026
7 shares @ US$42.735 Common Stock SEC:0001193125-26-323637:1
▼ Chief Executive Officer · Executives · 14 Jul 2026
5,481 shares @ US$39.7217 0.011% mcap 11.9% of flow Common Stock SEC:0001193125-26-304786:0
▼ Chief Executive Officer · Executives · 14 Jul 2026
2,729 shares @ US$40.5724 0.0056% mcap 6.1% of flow Common Stock SEC:0001193125-26-304786:1
▼ Chief Executive Officer · Executives · 29 Jun 2026
876 shares Common Stock SEC:0001193125-26-292519:1
▼ Chief Executive Officer · Executives · 29 Jun 2026
7,344 shares Common Stock SEC:0001193125-26-292519:0
● Officer · Executives · 30 Jun 2026
10,000 shares @ US$40.39 0.021% mcap 100.0% of flow Common SEC144:0001950047-26-006648
● Officer · Executives · 29 Jun 2026
99,480 shares @ US$40.39 0.21% mcap 100.0% of flow Common SEC144:0001958244-26-000411
▼ Chief Development Officer · Executives · 17 Apr 2026
20,225 shares @ US$39.9923 0.041% mcap 100.0% of flow Common Stock SEC:0001193125-26-167091:0
▼ 10% Owner · Executives · 17 Apr 2026
426,005 shares @ US$40.317 0.88% mcap 100.0% of flow Common Stock SEC:0001193125-26-167636:0
▼ Chief Development Officer · Executives · 10 Apr 2026
500 shares @ US$34.98 0.0009% mcap 1.2% of flow Common Stock SEC:0001193125-26-154908:0
▼ Chief Development Officer · Executives · 13 Apr 2026
9,165 shares @ US$34.974 0.016% mcap 21.3% of flow Common Stock SEC:0001193125-26-154908:1
▼ Chief Development Officer · Executives · 14 Apr 2026
10,200 shares @ US$35.0781 0.018% mcap 23.7% of flow Common Stock SEC:0001193125-26-154908:2
▼ Chief Development Officer · Executives · 8 Apr 2026
360 shares @ US$34.90 0.8% of flow Common Stock SEC:0001193125-26-149725:0
▼ Chief Operating Officer · Executives · 30 Mar 2026
7,161 shares @ US$28.0401 71.2% of flow Common Stock SEC:0001193125-26-134684:0
▼ Chief Operating Officer · Executives · 30 Mar 2026
2,839 shares @ US$28.553 28.8% of flow Common Stock SEC:0001193125-26-134684:1
▼ Chief Development Officer · Executives · 25 Mar 2026
10,115 shares @ US$29.9906 16.9% of flow Common Stock SEC:0001193125-26-126410:0
▼ Chief Operating Officer · Executives · 5 Mar 2026
2,014 shares @ US$28.93 16.1% of flow Common Stock SEC:0001193125-26-098488:0
▼ Chief Executive Officer · Executives · 18 Feb 2026
3,552 shares @ US$29.0516 6.6% of flow Common Stock SEC:0001193125-26-059886:0
▼ Chief Scientific Officer · Executives · 17 Feb 2026
900 shares @ US$28.0211 1.7% of flow Common Stock SEC:0001193125-26-059883:0
▼ Chief Executive Officer · Executives · 20 Jan 2026
5,833 shares @ US$26.1158 9.9% of flow Common Stock SEC:0001193125-26-019820:0
▼ Chief Scientific Officer · Executives · 15 Jan 2026
8,300 shares @ US$26.8255 15.1% of flow Common Stock SEC:0001193125-26-015350:0
◆ Chief Scientific Officer · Executives · 31 Dec 2025
18,000 shares Common Stock SEC:0001193125-26-002470:0
◆ Chief Development Officer · Executives · 31 Dec 2025
9,000 shares Common Stock SEC:0001193125-26-002469:0
▼ Chief Executive Officer · Executives · 17 Dec 2025
2,441 shares @ US$28.8378 5.5% of flow Common Stock SEC:0001193125-25-324826:0
25 of 50 declarations
Load more (25 remaining) About Rapport Therapeutics, Inc. Rapport Therapeutics, Inc. is a company focused on developing innovative treatments for neurological diseases. It is listed on the XNAS market.